Ranbaxy buys Ochoa Labs’ skin care range

Date: 22-05-2009

Ranbaxy Laboratories Ltd has acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories Ltd (Ochoa) for its entire range of dermatological and lifestyle products. The acquired brands command considerable equity with doctors and are market leaders in their respective categories. They complement Ranbaxy’s existing derma portfolio.

The products enjoy high margins because of their novelty and brand appeal and will be initially marketed in India. The deal size was not revealed by the company. The move strengthens Ranbaxy’s domestic presence and market share in dermatology, a high-growth therapeutic segment, for the company.

The current market size of the dermatology segments in India is approximately Rs 1,950 crore, growing rapidly at about 11 per cent. Ochoa has over 80 products which have now been acquired by Ranbaxy. Ranbaxy already has presence in the dermatology market, including steroids, with products such as Zole-F, Suncros, Efflora, Fucidin and Teczine, among others. crack crack